Evidence map›Paper›PMID 41629374›Full record

ArticleScientific reports2026

Sustainable dual-drug analysis: a synchronous spectrofluorimetric approach with integrated greenness and whiteness metrics for favipiravir and levofloxacin.

Hany A Batakoushy, Asmaa Othman El-Demerdash, Ashraf M Taha, Ola M Abdallah, Asmaa Abbas Nazer

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hany A BatakoushyDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Menoufia University, Shebin Elkom, 32511, Egypt.
Asmaa Othman El-DemerdashPharmaceutical Analytical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt. asmaaothman.pharmg@azhar.edu.eg.ORCID http://orcid.org/0000-0003-1613-1534
Ashraf M TahaB.Sc. of Pharmaceutical Sciences, Faculty of Pharmacy, Sinai University, Al-Arish, Egypt.
Ola M AbdallahPharmaceutical Analytical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Asmaa Abbas NazerB.Sc. of Pharmaceutical Sciences, Faculty of Pharmacy, Sinai University, Al-Arish, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innovative and sustainable synchronous spectrofluorimetric techniques were developed for the simultaneous assessment of favipiravir (FVP) and levofloxacin (LEV). Some COVID-19 treatment plans call for these drugs to be given together, so reliable approaches are needed to confirm that the studied drugs are of good quality. FVP and LEV are determined with high sensitivity in the nanogram per milliliter range, with high accuracy (recoveries of 99.34% ± 1.10 and 98.87% ± 0.44, respectively). Method validation was conducted in accordance with ICH guidelines. Moreover, several metric systems (Analytical Eco-Scale, GAPI, AGREE) are used to assess environmental sustainability, which confirms the greenness of the proposed method. Also, blueness and whiteness criteria (BAGI, RGB 12) were used to check the usefulness and analytical effectiveness of the established method. As this spectrofluorimetric method is simple, rapid, and inexpensive, it is preferred over other analytical techniques for the routine analysis of the drug combination in bulk powders and pharmaceutical formulations.

Indexed as

AmidesAntiviral AgentsLevofloxacinPyrazinesCOVID-19 Drug TreatmentSpectrometry, FluorescenceAmidesAntiviral AgentsfavipiravirLevofloxacinPyrazinesFavipiravir, levofloxacinGreennessSpectrofluorimetrySynchronousWhiteness

Identifiers

PMID41629374
PMCPMC12868843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.